CD274 and neoplasm: Currently, PD-L1 immunohistochemical (IHC) assays have the most FDA approvals as a companion diagnostic (CDx) for immunotherapy with immune checkpoint inhibitors in specific tumor types [1]; other immunotherapy predictive biomarker exist and will be briefly discussed in the next paragraph.